CRL: Ascending Triangle detected on 1 Apr 2026

CRL is forming an ascending triangle with resistance at $180.84 and support at $154.28, currently trading at $172.50. The pattern exhibits solid structure (10.0), excellent volume confirmation (12.0), and strong breakout potential (13.0) for an overall score of 74—indicating above-average pattern quality. Volume ratio of 1.3x average suggests healthy participation. RSI of 55.13 indicates neutral momentum, neither overbought nor oversold. The pattern follows a post-collapse recovery (29 days, moderate strength) and earlier double-bottom formation, reflecting resilience after significant drawdown.

Charles River announced planned divestitures expected to reduce 2026 reported revenue by slightly more than $200 million but lift non-GAAP EPS and margins. The company signed agreements to sell its CDMO and Cell Solutions businesses (generating $143 million 2025 revenue) to GI Partners, and divest certain European Discovery Services assets (generating $144 million 2025 revenue) to IQVIA for approximately $145 million. The divestitures are expected to generate at least 100 basis points of incremental non-GAAP operating margin improvement in 2026 and add approximately $0.10 to non-GAAP EPS for the partial year. Fourth-quarter 2025 results showed slightly lower revenue of $994.23 million and a net loss driven in part by $210.97 million of intangible asset impairments and $165 million of goodwill impairments. Long-time Chair and CEO James C. Foster will retire, with Chief Operating Officer Birgit Girshick becoming Chief Executive Officer. The pattern is forming amid portfolio restructuring and leadership transition intended to restore profitable growth.

A successful breakout above $180.84 resistance would target the conservative measured move of $183.11, representing roughly 6% upside from current levels. The setup indicates a win probability of 62.53%, suggesting better-than-random odds of profitable continuation. Volume should sustain above the 1.3x current ratio during the breakout to confirm validity. The invalidation level sits at $154.28 support—a decisive close below this price would signal pattern failure and shift the technical bias lower. Historical ascending triangle patterns with this quality score typically deliver 50-80 basis point moves before rotation.

The biggest risk is that ongoing demand softness and cancellations in key services persist, with management's main short-term catalyst being the effort to restore profitable growth after a loss-making 2025. Revenue declined 2.6% organically in Q4 2025, driven primarily by the Discovery and Safety Assessment (DSA) and Manufacturing Solutions segments. The stock declined 25.54% in the last 30 days after earnings and showed 1-year negative returns of 4.10%, suggesting momentum has cooled. Beta of 1.76 indicates elevated volatility versus the market, amplifying both gains and losses. Key risks include pricing pressure from aggressive CRO competitors and whether management can translate expanding partnerships into sustained revenue growth and better margins. High volatility (20-day: 0.599) and bearish market regime (-0.34 score) create headwinds for breakout follow-through. The May 5, 2026 shareholder meeting adds near-term event risk around governance approval.